Q2 EPS Estimate for Connect Biopharma Decreased by Analyst

Connect Biopharma Holdings Limited (NASDAQ:CNTB) – Analysts at HC Wainwright lowered their Q2 2025 earnings per share (EPS) estimates for shares of Connect Biopharma in a note issued to investors on Tuesday, April 1st. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of ($0.27) per share for the quarter, down from their prior estimate of ($0.26). HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Connect Biopharma’s current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Connect Biopharma’s Q3 2025 earnings at ($0.29) EPS.

Connect Biopharma Trading Up 6.8 %

Shares of CNTB stock opened at $0.63 on Friday. The company has a 50 day moving average price of $0.85 and a 200-day moving average price of $1.05. Connect Biopharma has a 52 week low of $0.51 and a 52 week high of $2.29.

Institutional Investors Weigh In On Connect Biopharma

A number of large investors have recently added to or reduced their stakes in the stock. Catalina Capital Group LLC purchased a new position in shares of Connect Biopharma in the 4th quarter worth $66,000. Callan Capital LLC boosted its position in Connect Biopharma by 91.3% in the fourth quarter. Callan Capital LLC now owns 80,000 shares of the company’s stock worth $110,000 after purchasing an additional 38,177 shares during the last quarter. Finally, Choreo LLC purchased a new position in Connect Biopharma in the fourth quarter worth about $204,000. Institutional investors own 58.72% of the company’s stock.

Connect Biopharma Company Profile

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.